Australian biotech company All G has become the ‘first in the world’ to receive regulatory approval to sell recombinant bovine lactoferrin in China.

All G uses precision fermentation to develop high-value, animal-free proteins for use in a variety of markets – from functional foods to medical and infant nutrition.

This approval allows for the sale of All G's product into a specific target market, which the company says it will disclose closer to the time of market entry. All G is simultaneously progressing with regulatory approval for the use of its lactoferrin in infant formula, which is expected in 2025.

The approval will enable All G to bring in initial revenue streams in advance of its Series B fundraise. All G aims to produce at or below price parity compared with conventionally produced lactoferrin and expects to release its first lactoferrin product in 2025, with plans to receive approval for its products in the US, Australia, New Zealand and Japan.

Lactoferrin, a whey protein found in human and cow’s milk, is sought-after for its functional benefits, including enhancing gut function, iron absorption and providing antimicrobial and anti-inflammatory benefits. However, due to its low concentration in cow's milk, it is expensive to produce and yields only limited quantities, creating a major opportunity for alternative protein producers. China is one of the largest consumers of lactoferrin globally, driven by a growing demand for functional foods and health-conscious consumers.

All G CEO Jan Pacas said: “This approval is a great moment for All G as we lead the way in precision fermentation technology. Lactoferrin is one of the most valuable and functional proteins in the world. Our technology unlocks its potential, and this is just the beginning – our recombinant human lactoferrin is progressing rapidly, with many other products in the pipeline.”

Jim Mellon, Agronomics' executive chair, added: “All G is one of the leading technology companies developing animal-free proteins and achieving regulatory approval for lactoferrin in China – the world's largest market – is an exciting step for the industry. More importantly, it provides a platform from which All G can bring other key products to market at competitive prices.”

#AllG #China #lactoferrin #Australia